30 March 2022 in Clinical and Experimental Health Sciences
Objective: The objective of this study was to develop triamcinolone acetonide (TAA) loaded poly(lactide-co-glycolic acid) (PLGA) dry powder inhaler (DPI) formulations by using spray dryer and to characterize the formulations with reference to their appropriateness for pulmonary drug delivery. Methods: PLGA dry powder inhalers containing TAA were produced in two stages. In the first step, PLGA microparticles were prepared by emulsion-solvent evaporation method and the DPI formulations were produced by the spray-drying process using mannitol and leucine. TAA loaded PLGA DPI was classified physicochemical properties. The in vitro dissolution test was carried out using modified USP apparatus 2. Aerosol performance was identified with next generation impactor. Results: This study has demonstrated that TAA loaded PLGA DPI were effectively prepared. Scanning electron microscope illustrates the spherical shape, particle size (D50) was established to be between 2.7-3.1 µm and all formulations charged negatively. Special chemical interaction in the DPI was not observed by FT-IR. The in vitro aerosol performance study represented DPI formulations have the proper aerodynamic properties for targeting the lungs. The in vitro TAA release from DPI formulations decreased with increasing of PLGA concentration. Conclusion: Developed PLGA dry powder inhaler formulations containing TAA have shown suitable aerodynamic characteristics to be administered to the lungs thereby could improve in the management of asthma by increasing TAA residency in the lungs for a prolonged period of time.
1 January 2021 in Journal of Dr Behcet Uz Children s Hospital
Objective: Allergic rhinitis (AR) is an inflammatory disease of the nasal mucosa mediated by IgE after exposure to an allergen. The most well known related comorbidity of AR is asthma. This study was planned due to the need for an animal model for studies on AR-asthma coexistence. In this study, the frequency of AR accompanying in the asthma model created in mice,and the usability of the related model in AR studies will be investigated. Methods: In our study, 6-8 week-old, 18-20 g BALB/c mice were used. Chicken egg ovalbumin (OVA Grade V, Sigma) was administered through intraperitoneal (IP) route at doses of 10 μg on days 0 and 14. Mice were exposed to aerosolized 2.5% ovalbumin solution in sterile saline for 30 minutes 3 days a week for 8 weeks, starting 7 days after the last IP administration (21st day). After exposure to OVA, mice were observed for typical signs of AR including sneezing, runny nose, and nasal itching. The final diagnosis of AR was made by histopathological examination of the rhinotracheal tissues of mice. Results: In our study, all mice exposed to ovalbumin received histopathologic diagnosis of AR. Increased number of capillaries lymphocytes, polymorphonuclear leukocytes and eosinophilsper square millimetre of rhinotracheal tissues were calculated in the murine model of AR compared to the the control group. Conclusion: This study introduced a new AR model, not cited in the literature, and induced with the longest-term ovalbumin exposure in the literature. It was concluded that this model, known as the asthma model, can also be used to induce an AR model and can be used in studies investigating coexistence of allergic rhinitis and asthma.